Top Report on China Human Vaccine Industry Report, 2015-2018

Submitted by: Submitted by

Views: 27

Words: 528

Pages: 3

Category: Business and Industry

Date Submitted: 03/26/2015 10:57 PM

Report This Essay

ResearchMoz.us include new market research report " China Human Vaccine Industry Report, 2015-2018: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies’ (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China’s human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

View report details with TOC at: http://www.researchmoz.us/china-human-vaccine-industry-report-2015-2018-report.html

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.

However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume....